SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.
prnewswire.com
news
2022-06-03 18:12:00

NEW YORK, June 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point Therapeutics, Inc. ("Turning Point" or the "Company") (NASDAQ: TPTX), in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company (NYSE: BMY) via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $76.00 in cash for each share of Turning Point common stock owned.
